AVROBIO (AVRO) Q3 2024 earnings summary

Executive summary

• Lead asset TX45 advanced through Phase 1b and Phase 2 trials for Group 2 Pulmonary Hypertension in HFpEF, with topline Phase 1b results expected in late Q1 or early Q2 2025 and Phase 2 in 2026.

• Patient enrollment in the Phase 1b TX45 trial is ahead of expectations; first subject dosed in APEX Phase 2 trial in October 2024.

• TX2100 selected as development candidate for HHT, with Phase 1 trial initiation targeted for late 2025 or early 2026.

• Completed reverse merger with AVROBIO in June 2024, raising $96.6 million via Subscription Agreement and acquiring $85.2 million in cash, resulting in $159.1 million in cash and equivalents as of September 30, 2024.

• Management expects current cash to fund operations into mid-2027, but anticipates continued operating losses and the need for additional capital for future development and commercialization.

Financial highlights

• Cash and cash equivalents were $159.1 million as of September 30, 2024, down from $185.1 million as of June 30, 2024.

• Net loss for Q3 2024 was $17.7 million, compared to $10.1 million in Q3 2023.

• Research and development expenses for Q3 2024 were $14.3 million, up 76% from Q3 2023, mainly due to TX45 clinical trial progression and early-stage pipeline activities.

• General and administrative expenses for Q3 2024 were $5.3 million, up 169% year-over-year, reflecting higher stock-based compensation, merger-related, and personnel costs.

• Cash runway is expected to extend into mid-2027, covering key clinical milestones.

Outlook and guidance

• Topline results from the TX45 Phase 1b trial are expected in late Q1 or early Q2 2025; Phase 2 APEX trial topline data anticipated in 2026.

• Phase 1 trial for TX2100 in HHT is planned for late 2025 or early 2026, pending IND-enabling studies.